Thanks for your thoughts Mozz. I worry about the capital...

First 3515 Last

Share
Profile

Follow
tradepunk

145 Posts.

27

25/01/23

18:56

Post #: 65884120
Share

Originally posted by Mozzarc: ↑

TradePunk...interesting question.

Indeed while there may not be a formal definition and criteria, read endpoints, stipulated by the FDA, there are certainly bodies of proof that will satisfy them.

Some that I think would have to be met include, but may not be limited to:

1) Hard Cord Clinical observations of the standard...eg Pain and Function WOMAC score improvement to baseline and subsequent comparison to placebo.

2) Some sorta prognostic biomarker, that acts as a surrogate. We know OA typically progress over lengthy period of time, ie 10 years generally. Show us some proof of reducing, arresting or even reversing of this biomarker and it will go a long way to getting that label where we need it!

3) All of the above but ideally we want an immaculate safety record please.

Point 2) could be as Dr V Kraus suggests, CTX II, but there are others on the hit list, namely HA as well as COMP as examples.

All of the above would be fairly much base level requirement. Now add any clinically significant structural biomarkers going the right way, and it may only be in smaller numbers and I think you'd have a drug safely over the line in terms of label making where DMOAD is concerned. At the end of the day what do the FDA want?

They want a safe drug that works and ideally at least in a good amount proportion of patients, then there is a good chance of DMOAD being accredited to the all important label.

Faster pathways are possible. I also think some sorta study would need to be set up in a formalised clinical setting but Accelerated utilising the surrogate endpoint(s) is a rapid way to get this done...and in our case I do rate it as a chance. Don't also forget, ordinarily you would want to see numbers...ie larger patient numbers, the whole purpose for a P3 for instance. But having achieved Statistical Significance already in such an incredibly tiny cohort is gold for us. This should in theory allow us to conduct a future trial with manageable numbers based on powering of the trial and drug effect size.

Get that (AA) and of course we will still want an NDA eventually and thus full licence but in the interim, this will be a very very big turning point for us.

The SP would no doubt agree at this juncture.

My thoughts

Expand

Thanks for your thoughts Mozz. I worry about the capital requirements should it drag on for too long but I also understand the label makes it so much more valuable. I’ll keep holding and make the decision down the track about giving them more money to avoid dilution or taking it on the chin.

PAR Price at posting: $1.40 Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

Making money: How many microcaps should be in an investor's portfolio?

Finance school vs reality: What they don't teach you about the stock market

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

There are more pages in this discussion • 929 more messages in this thread...

First 3515 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 20.5¢		Change -0.005(2.38%)		Mkt cap ! $71.73M

Open	High	Low	Value	Volume
21.0¢	21.0¢	19.5¢	$323.1K	1.612M

Buyers (Bids)

No.	Vol.	Price($)
1	324	20.5¢

Sellers (Offers)

Price($)	Vol.	No.
21.0¢	52928	5

View Market Depth

No.	Vol.	Price($)
1	324	0.205
4	51564	0.200
6	188903	0.195
19	418023	0.190
7	134000	0.185

Price($)	Vol.	No.
0.210	52928	5
0.215	16833	2
0.220	23800	4
0.225	42062	1
0.230	78202	7

Last trade - 16.10pm 28/10/2024 (20 minute delay)

PAR (ASX) Chart

Thanks for your thoughts Mozz. I worry about the capital...

Making money: How many microcaps should be in an investor's portfolio?

Finance school vs reality: What they don't teach you about the stock market

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thanks for your thoughts Mozz. I worry about the capital...

Top Stories

Making money: How many microcaps should be in an investor's portfolio?

Finance school vs reality: What they don't teach you about the stock market

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News